Legend Biotech's BCMA CAR-T Therapy Carvykti Achieves $1.887 Billion in Global Sales in 2025

▎Armstrong

On January 21, 2026, Johnson & Johnson released its 2025 financial report, with innovative drug sales revenue reaching $60.4 billion, a year-on-year increase of 5.3%.

From the Q4 data, oncology and neuroscience drugs contributed to the main growth of the innovative drug business.

Legend Biotech's Partnered BCMA CAR-T Therapy Carvykti Achieves $555 Million in Q4 Sales, $1.887 Billion in Annual Sales, a Year-on-Year Increase of 95.9%; Sales Projected to Exceed $3 Billion by 2026 Based on Current Growth Trends.

Carvykti to Reach Blockbuster Status by 2025, Achieving Super Blockbuster Status This Year.

Summary

Carvykti has already turned profitable, with future peak sales expected to exceed $5 billion. Legend Biotech is anticipated to achieve operational profitability at the corporate level by 2026. Carvykti also represents another classic case of commercial success in the international market following zanubrutinib.